Back to Journals » ImmunoTargets and Therapy » Volume 3
ImmunoTargets and Therapy
ISSN: 2253-1556
- View all (180)
- Volume 13, 2024 (25)
- Volume 12, 2023 (14)
- Volume 11, 2022 (6)
- Volume 10, 2021 (30)
- Volume 9, 2020 (27)
- Volume 8, 2019 (5)
- Volume 7, 2018 (10)
- Volume 6, 2017 (8)
- Volume 5, 2016 (8)
- Volume 4, 2015 (17)
- Volume 3, 2014 (14)
- Volume 2, 2013 (13)
- Volume 1, 2012 (3)
Archive: Volume 3, 2014
Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy
Drakes ML, Stiff PJ
ImmunoTargets and Therapy 2014, 3:151-165
Published Date: 4 December 2014
Therapeutic cancer vaccines and combination immunotherapies involving vaccination
Nguyen T, Urban J, Kalinski P
ImmunoTargets and Therapy 2014, 3:135-150
Published Date: 6 October 2014
Nanocarrier-based immunotherapy in cancer management and research
Singh MS, Bhaskar S
ImmunoTargets and Therapy 2014, 3:121-134
Published Date: 26 June 2014
Hairy cell leukemia – immunotargets and therapies
Basheer F, Bloxham DM, Scott MA, Follows GA
ImmunoTargets and Therapy 2014, 3:107-120
Published Date: 24 June 2014
Immunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation
Keller MD, Bollard CM
ImmunoTargets and Therapy 2014, 3:97-106
Published Date: 18 June 2014
Clinical potential of apremilast in the treatment of psoriatic arthritis
Cauli A, Porru G, Piga M, Vacca A, Dessole G, Mathieu A
ImmunoTargets and Therapy 2014, 3:91-96
Published Date: 9 June 2014
Antigen-based immunotherapy for the treatment of acute lymphoblastic leukemia: the emerging role of blinatumomab
Litzow MR
ImmunoTargets and Therapy 2014, 3:79-89
Published Date: 9 April 2014
Emerging options for the treatment of melanoma – focus on ipilimumab
Roddie C, Peggs KS
ImmunoTargets and Therapy 2014, 3:67-78
Published Date: 17 March 2014
Dendritic cell vaccination for glioblastoma multiforme: review with focus on predictive factors for treatment response
Dejaegher J, Van Gool S, De Vleeschouwer S
ImmunoTargets and Therapy 2014, 3:55-66
Published Date: 13 March 2014
Interleukin-17 and type 17 helper T cells in cancer management and research
Llosa NJ, Geis AL, Thiele Orberg E, Housseau F
ImmunoTargets and Therapy 2014, 3:39-54
Published Date: 10 March 2014
B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292
Arnason JE, Brown JR
ImmunoTargets and Therapy 2014, 3:29-38
Published Date: 24 January 2014
Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?
Castillo-Carranza DL, Guerrero-Muñoz MJ, Kayed R
ImmunoTargets and Therapy 2014, 3:19-28
Published Date: 27 December 2013
Implications of chemokine receptors and inflammatory lipids in cancer
Rolin J, Maghazachi AA
ImmunoTargets and Therapy 2014, 3:9-18
Published Date: 24 December 2013
Emerging treatments in management of prostate cancer: biomarker validation and endpoints for immunotherapy clinical trial design
Slovin SF
ImmunoTargets and Therapy 2014, 3:1-8
Published Date: 17 December 2013